Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Depreciation & Amortization (CF) (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $128000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 33.68% to $128000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $633000.0 through Dec 2025, down 20.38% year-over-year, with the annual reading at $633000.0 for FY2025, 20.38% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $128000.0 at Phathom Pharmaceuticals, down from $156000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $214000.0 in Q1 2024, with the low at $121000.0 in Q3 2023.
  • Average Depreciation & Amortization (CF) over 4 years is $163937.5, with a median of $170000.0 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 60.16% in 2024, then tumbled 33.68% in 2025.
  • Over 4 years, Depreciation & Amortization (CF) stood at $168000.0 in 2022, then rose by 10.12% to $185000.0 in 2023, then grew by 4.32% to $193000.0 in 2024, then crashed by 33.68% to $128000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $128000.0, $156000.0, and $172000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.